Memantine for Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: Memantine, an NMDA receptor uncompetitive antagonist, is currently approved by the Food and Drug Administration for the treatment of moderate to severe Alzheimer’s disease. Anecdotal reports have suggested that memantine may improve neurological and cognitive symptoms of individuals with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Psychiatry
Главные авторы: Seritan, Andreea L., Nguyen, Danh V., Mu, Yi, Tassone, Flora, Bourgeois, James A., Schneider, Andrea, Cogswell, Jennifer, Cook, Kylee, Leehey, Maureen, Grigsby, Jim, Olichney, John M., Adams, Patrick, Legg, Wendi, Zhang, Lin, Hagerman, Paul, Hagerman, Randi J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296896/
https://ncbi.nlm.nih.gov/pubmed/24345444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.13m08546
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы